Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.50 |
| ▸ | CDK4 | P11802 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | XBP1 | P17861 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | CDK1 | P06493 | 2/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.50 |
| ▸ | CCND1 | P24385 | 2/20 | 0.50 |
| ▸ | CDK7 | P50613 | 2/20 | 0.50 |
| ▸ | CCNH | P51946 | 2/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | CDK9 | P50750 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3605169 | 0.90 | CDK2 (0.51) | CDK2MAPTCDK5CDK5R1CDK4 | |
| SCHEMBL3608990 | 0.89 | MAPT (0.52) | CDK2MAPTCDK5CDK5R1CDK4 | |
| SCHEMBL3611125 | 0.88 | MAPT (0.52) | CDK2MAPTCDK5CDK5R1CDK4 | |
| SCHEMBL3611150 | 0.88 | CDK2 (0.50) | CDK2MAPTCDK5CDK5R1CDK4 | |
| SCHEMBL3609176 | 0.87 | CDK2 (0.49) | CDK2MAPTCDK5CDK5R1CDK4 | |
| SCHEMBL3608870 | 0.86 | CAMK2D (0.57) | CDK2MAPTCDK5CDK5R1CDK4 | |
| SCHEMBL3608421 | 0.86 | CDK2 (0.52) | CDK2MAPTCDK5CDK5R1CDK4 | |
| SCHEMBL3602892 | 0.85 | CDK1 (0.58) | CDK2MAPTCDK5CDK5R1CDK4 | |
| SCHEMBL3617376 | 0.85 | CDK2 (0.51) | CDK2MAPTCDK5CDK5R1CDK4 | |
| SCHEMBL3607412 | 0.84 | ABL1 (0.52) | CDK2MAPTCDK5CDK5R1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048597-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | CDK2 3078/4885MAPT 1424/4885CDK5 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.